In the BioHarmony Drug Report Database

"Preview" Icon

Tazemetostat

Tazverik (tazemetostat) is a small molecule pharmaceutical. Tazemetostat was first approved as Tazverik on 2020-01-23. The pharmaceutical is active against histone-lysine N-methyltransferase EZH2. Tazverik’s patents are valid until 2035-12-19 (FDA).

 

Trade Name

 

Tazverik
 

Common Name

 

tazemetostat
 

ChEMBL ID

 

CHEMBL3414621
 

Indication

 

 

Drug Class

 

Enzyme inhibitors

Image (chem structure or protein)

Tazemetostat structure rendering